沙利度胺对人卵巢癌裸鼠皮下种植瘤抑瘤作用的研究  

Study of thalidomide on the growth inhibition of ovary cancer SKOV-3 subcutaneous implanted in nude mice

作　　者：杜娟[1] 黄学惠[1] 

机构地区：[1]昆明医学院第一附属医院妇科,云南昆明650032

出　　处：《现代肿瘤医学》2011年第2期245-248,共4页Journal of Modern Oncology

基　　金：云南省教育厅资助课题(编号:08c0103)

摘　　要：目的:探讨沙立度胺(反应停,酞咪哌啶酮,thalidomide)对卵巢癌裸鼠皮下种植瘤的生长抑制作用。方法:建立20只卵巢癌裸鼠荷瘤模型,随机分为4组,每组5只:沙利度胺组:按200mg.kg-1d-1,0.2ml腹腔内注射。顺铂组:2mg.kg-1d-1,0.2ml腹腔内注射。联用组:顺铂与沙利度胺联合应用(顺铂2mg.kg-1d-1,沙利度胺200mg.kg-1d-1,各0.2ml腹腔内注射)。生理盐水组:每只0.2ml生理盐水腹腔内注射。4组给药方法均为自肿瘤种植成功后瘤体直径平均为0.8cm,开始给药,给药2周,每周2次,总共注射4次。观察各组裸鼠体重、皮下种植瘤瘤体直径均值(MTD)的变化,以及各组裸鼠的行动、对外界刺激的反应、饮食、及瘤体表面皮肤的变化,测量各组肿瘤的大小。结果:沙利度胺组、顺铂组、联用组荷瘤体积明显小于生理盐水组,差异有统计学意义(P<0.05),抑瘤率分别为57.47%、42.18%、71.37%。结论:沙利度胺对卵巢癌皮下种植瘤的生长有抑制作用,与传统的化疗药物顺铂联用,可增强化疗药物作用。Objective：To study the effect of thalidomide used alone and in combi -nation with cisplatin（DDP） on ovarian cancer cell subcutaneous implanted tumor gro - wth inhibition. Methods- Twenty ovarian cancer modle ubcutaneous implantted in nude m - ice was established and randomly divided into 4 groups, n = 5 ： thalidomide group： 200mg · kg-1·d-1, 0.2ml, ip;DDPgroup： 0.2mg· kg-1·d-1, 0. 2ml, ip.;Combined treatment group： both Thd and DDP, 0.2ml, ip;control group： saline solution, 0.2ml, ip. After the success of implant, MTD 0.8cm, administered two weeks, twice a week, total of 4 injection. Weight, MTD changes, the actions of nude mice, the response to external stimulation, food, the surface of skin tumor changes and measured tumor inhibition rate was observed in each group. Results： Compared with the control group, growth of tumor was significantly reduced in mice treated with thalidomide, DDP and combined treatment. （ inhibition rate 57.47%, 42.18%, 71.37% ） （P 〈 0.05 ）. Conclusion： Thalidomide can inhibit the growth of human ovarian cancer subcutaneous implanted in nude mice. In colnbination with DDP, thalidomide might prove the antitumor drug therapy.

关 键 词：沙利度胺 顺铂 卵巢癌 裸鼠 生长抑制 

分 类 号：R737.31[医药卫生—肿瘤]